Literature DB >> 32485175

p38 mitogen-activated protein kinase and pain.

Lijia Mai1, Xiao Zhu2, Fang Huang3, Hongwen He3, Wenguo Fan4.   

Abstract

Inflammatory and neuropathic pain is initiated by tissue inflammation and nerve injury, respectively. Both are characterized by increased activity in the peripheral and central nervous system, where multiple inflammatory cytokines and other active molecules activate different signaling pathways that involve in the development and/or maintenance of pain. P38 mitogen-activated protein kinase (MAPK) is one member of the MAPK family, which is activated in neurons and glia and contributes importantly to inflammatory and neuropathic pain. The aim of this review is to summarize the latest advances made about the implication of p38 MAPK signaling cascade in pain. It can deepen our understanding of the molecular mechanisms of pain and may help to offer new targets for pain treatment.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Glial cells; Pain; p38 MAP kinase

Year:  2020        PMID: 32485175     DOI: 10.1016/j.lfs.2020.117885

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  12 in total

Review 1.  Multifactorial pathways in burn injury-induced chronic pain: novel targets and their pharmacological modulation.

Authors:  Tapas Kumar Roy; Ankit Uniyal; Akhilesh Vinod Tiwari
Journal:  Mol Biol Rep       Date:  2022-07-17       Impact factor: 2.742

2.  Phosphorylated MAPK14 Promotes the Proliferation and Migration of Bladder Cancer Cells by Maintaining RUNX2 Protein Abundance.

Authors:  Junlong Liu; Xiuyue Yu; Bitian Liu; Hongyuan Yu; Zhenhua Li
Journal:  Cancer Manag Res       Date:  2020-11-06       Impact factor: 3.989

3.  Network Pharmacology-Based Analysis of the Underlying Mechanism of Huajiao for Pain Relief.

Authors:  Mingquan Wu; Hong-Ling Du; Xu Zhou; Wei Peng; Limei Liu; Zhong Zhang; He Tu
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-04       Impact factor: 2.629

4.  The p38/MK2 Axis in Monocytes of Fibromyalgia Syndrome Patients: An Explorative Study.

Authors:  Boya Nugraha; Renate Scheibe; Christoph Korallus; Matthias Gaestel; Christoph Gutenbrunner
Journal:  Medicina (Kaunas)       Date:  2021-04-19       Impact factor: 2.430

5.  Analysis of Prognostic Risk Factors of Sepsis Patients in Intensive Care Unit Based on Data Analysis.

Authors:  Lina Yao; Lei Zhang; Chengjie Zhou
Journal:  J Healthc Eng       Date:  2022-01-07       Impact factor: 2.682

6.  Amelioration of Neuropathic Pain and Attenuation of Neuroinflammation Responses by Tetrahydropalmatine Through the p38MAPK/NF-κB/iNOS Signaling Pathways in Animal and Cellular Models.

Authors:  Cheng Hu; Menglin He; Meijuan Chen; Qian Xu; Sha Li; Yaomei Cui; Xizi Qiu; Weiqian Tian
Journal:  Inflammation       Date:  2021-11-10       Impact factor: 4.092

Review 7.  Recent Advances in Pain Management: Relevant Protein Kinases and Their Inhibitors.

Authors:  Francis Giraud; Elisabeth Pereira; Fabrice Anizon; Pascale Moreau
Journal:  Molecules       Date:  2021-05-04       Impact factor: 4.411

8.  NFAT5 Deficiency Alleviates Formalin-Induced Inflammatory Pain Through mTOR.

Authors:  Do Hyeong Gwon; Song I Kim; Seoung Hun Lee; Chan Noh; Yeojung Kim; Sangwon Yun; Won Hyung Lee; Jun Young Oh; Dong Woon Kim; Jinpyo Hong; Sun Yeul Lee
Journal:  Int J Mol Sci       Date:  2021-03-04       Impact factor: 5.923

9.  Spinal cord stimulation reduces cardiac pain through microglial deactivation in rats with chronic myocardial ischemia.

Authors:  Jian Wang; Xiao-Chen Wu; Ming-Ming Zhang; Jia-Hao Ren; Yi Sun; Jing-Zhen Liu; Xi-Qiang Wu; Si-Yi He; Yun-Qing Li; Jin-Bao Zhang
Journal:  Mol Med Rep       Date:  2021-10-05       Impact factor: 2.952

10.  Protein arginine methyltransferase 7 modulates neuronal excitability by interacting with NaV1.9.

Authors:  Tingbin Ma; Lulu Li; Rui Chen; Luyao Yang; Hao Sun; Shiyue Du; Xuan Xu; Zhijian Cao; Xianwei Zhang; Luoying Zhang; Xiaoliu Shi; Jing Yu Liu
Journal:  Pain       Date:  2022-04-01       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.